Kura Oncology, Inc. (KURA) vs MoonLake Immunotherapeutics (MLTX)
A side-by-side comparison of Kura Oncology, Inc. and MoonLake Immunotherapeutics across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KURA
Kura Oncology, Inc.
$10.43HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
MLTX
MoonLake Immunotherapeutics
$10.98HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — KURA vs MLTX
growth of $100 · dividends reinvested · last 6yKURA -68.9% (-17.7%/yr)MLTX +8.5% (+1.4%/yr)MLTX compounded faster over this window
KURA MLTX
KURA vs MLTX: by the numbers
- •KURA is the larger company ($926M vs $923M market cap).
- •Both run net losses; MLTX's is the smaller (0.00% vs -384.30% net margin).
Metrics side by side
Valuation
| Metric | KURA | MLTX |
|---|---|---|
| P/S ratio | 11.99 | N/A |
| P/B ratio | 19.12 | 2.16 |
Profitability
| Metric | KURA | MLTX |
|---|---|---|
| Gross margin | 94.73% | 0.00% |
| Operating margin | -449.94% | 0.00% |
| Net margin | -384.30% | 0.00% |
| ROE | -612.78% | -61.58% |
| ROIC | -67.13% | -50.77% |
Growth (annualized)
| Metric | KURA | MLTX |
|---|---|---|
| Total return CAGR (5Y) | -10.73% | 2.81% |
Frequently asked
- How have KURA and MLTX total returns compared?
- Over the past 5 years, KURA delivered -10.73% and MLTX delivered 2.81% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.